Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.

Ferrari M, Martignoni E, Blandini F, Riboldazzi G, Bono G, Marino F, Cosentino M.

Eur J Clin Pharmacol. 2012 Nov;68(11):1493-9. doi: 10.1007/s00228-012-1281-y. Epub 2012 Apr 15.

PMID:
22527346
2.

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.

Martignoni E, Cosentino M, Ferrari M, Porta G, Mattarucchi E, Marino F, Lecchini S, Nappi G.

Neurology. 2005 Dec 13;65(11):1820-2.

PMID:
16344532
3.

The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.

Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR.

Clin Neuropharmacol. 2000 May-Jun;23(3):143-8.

PMID:
10895397
4.

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.

Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO.

Neurology. 2002 Feb 26;58(4):564-7.

PMID:
11865133
5.

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.

Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M.

Pharmacogenet Genomics. 2008 Sep;18(9):815-21. doi: 10.1097/FPC.0b013e328306c2f2.

PMID:
18698234
6.

Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Henry C, Wilson JA.

Lancet. 1998 Jun 27;351(9120):1965-6. No abstract available.

PMID:
9654299
7.

The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.

Torkaman-Boutorabi A, Shahidi GA, Choopani S, Rezvani M, Pourkosary K, Golkar M, Zarrindast MR.

Acta Neurobiol Exp (Wars). 2012;72(3):272-82.

8.

Catechol-O-methyltransferase and Parkinson's disease.

Tai CH, Wu RM.

Acta Med Okayama. 2002 Feb;56(1):1-6. Review.

9.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
10.

The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.

Białecka M, Droździk M, Kłodowska-Duda G, Honczarenko K, Gawrońska-Szklarz B, Opala G, Stankiewicz J.

Acta Neurol Scand. 2004 Oct;110(4):260-6.

PMID:
15355491
11.

Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.

Ferreira JJ, Rocha JF, Falcão A, Santos A, Pinto R, Nunes T, Soares-da-Silva P.

Eur J Neurol. 2015 May;22(5):815-25, e56. doi: 10.1111/ene.12666. Epub 2015 Feb 4.

PMID:
25649051
12.

Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene.

Olson KC, Dellinger RW, Zhong Q, Sun D, Amin S, Spratt TE, Lazarus P.

Drug Metab Dispos. 2009 Oct;37(10):1999-2007. doi: 10.1124/dmd.108.024596. Epub 2009 Jul 9.

13.

Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.

Hao H, Shao M, An J, Chen C, Feng X, Xie S, Gu Z, Chan P; Chinese Parkinson Study Group.

Parkinsonism Relat Disord. 2014 Oct;20(10):1041-5. doi: 10.1016/j.parkreldis.2014.06.021. Epub 2014 Jul 4. Review.

PMID:
25034874
14.

Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.

Talati R, Reinhart K, Baker W, White CM, Coleman CI.

Parkinsonism Relat Disord. 2009 Aug;15(7):500-5. doi: 10.1016/j.parkreldis.2008.12.007. Epub 2009 Jan 22.

PMID:
19167259
15.

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.

Ann Neurol. 2011 Jan;69(1):111-8. doi: 10.1002/ana.22155.

PMID:
21280081
16.

Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.

Ramírez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, Ratain MJ.

Drug Metab Dispos. 2007 Dec;35(12):2149-53. Epub 2007 Aug 30.

17.
18.

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.

Lee MS, Lyoo CH, Ulmanen I, Syvänen AC, Rinne JO.

Neurosci Lett. 2001 Feb 2;298(2):131-4.

PMID:
11163295
19.

Clinical advantages of COMT inhibition with entacapone - a review.

Gordin A, Kaakkola S, Teräväinen H.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1343-63. Epub 2004 Aug 3. Review.

PMID:
15340869
20.

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

Deane KH, Spieker S, Clarke CE.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004554. Review.

PMID:
15495119

Supplemental Content

Support Center